Institution	Oklahoma State University - Center for Health Sciences
Meeting Date	Thursday, September 9, 2025
Meeting Time	10:00 AM
Meeting Type	Hybrid Meeting

IBC Members Present	Name	Role	Attendance
	Dr. Gerwald Koehler	Committee Chair	Present
	Dr. I-Hsiu (George) Huang	Scientific Member	Present
	Dr. Sue Katz Amburn	Non-affiliated Member	Present
	Dr. Crystal (Niki) Johnson	Scientific Member	Present
	William (BJ) Reddig	Lab representative	Present
	Dr. Fang (Fiona) Liu	Non-affiliated member	Present
	Dr. David Wallace	Animal Expert	Present
	Dr. Vikram Gujar	Alternate Member - Affiliated Scientist	Present, non-voting at this meeting
Quorum	Quorum is met. The IBC has seven (7) voting members present, and four (4) voting members are required to conduct business.		

Others in Attendance	Name	Affiliation	Title
	Kadin Falkensten	Oklahoma State University - Center for Health Sciences	Research Compliance Coordinator, Biosafety Officer

Call to Order	The IBC Chair called this meeting to order at 10:00am.		
Conflicts of Interest	The IBC Chair asked all members present to identify any conflicts of interest with the materials that are to be reviewed. Dr. Koehler disclosed that he has a conflict of interest with the review of IBC-00001241 and will recuse himself from the discussion of this application		
Discussion of previous minutes	No discussion was held regarding the August 21, 2025 meeting minutes. Dr. Wallace made the motion, and Dr. Johnson seconded.		
Review and Approval of	Date of previous meeting	Motion	Votes; for/against/abstain

previous meeting minutes	Thursday, August 21, 2025	Approve as written	7/0/0

Review of Prior Business	Business	Review and Discussion
	Report of pending/outstanding protocol(s)	At this meeting, there is currently one protocol awaiting review at the October IBC meeting: IBC-0001237. Additonal protocols are also likely to be reviewed at the upcoming meeting as a few applications are about to be renewed.
	Report of Biosafety Inspection Status	Kadin Falkensten gave the report of his biosafety inspection findings. At this time, the Biosafety Inspections of all laboratories on campus has been completed. No significant deficiencies were noted, and no recurring deficiencies were noted across all laboratories.

New IBC Registrations and Amendments for Review		
Review of IBC-00001241		
PI Name(s)	Dr. Gerwald Koehler	
Registration Title/Number	Use of human cell lines for tissue engineering and research on microbe-tissue interactions	IBC-00001241

Project Overview	The commercially available human cell lines Caco-2 (ATCC HTP-37), HEK-292 (ATCC 292), and Saos-2 (ATCC HTB-85) will be used to establish 2D- or 3D-cell culture systems for study of cell differentiation and tissue formation on scaffolds. Cell cultures will also be employed to investigate interactions with microbial cells or microbial culture supernatants (postbiotics). Human cell and engineered tissue co-cultures with microbes and their products can provide valuable insights into the pathogenesis of infectious diseases as well as the nature of beneficial interactions and interkingdom communications. Furthermore, employing these in vitro systems can help reduce the use of animal models. The microbes used in these co-culture studies include the beneficial bacteria Bacillus subtilis (Risk-group [RG] 1) and Lactobacillus species (RG 1) available in the PI's laboratory from previous studies. Additionally, the fungus Talaromyces purpureogenus (environmental isolates, RG1) and strains of the opportunistic fungal pathogen Candida albicans (RG 2) will be employed in co-culture experiments with the bacteria and/or human cell lines. An array of C. albicans gene deletion mutants and fluorescently labeled strains generated in previous work are available for the study. Plasmids for fluorescent/luminescent protein labeling of lactobacilli (pSIP411 derivatives expressing mCherry and CBRLuc, obtained from a research collaborator) and plasmids developed for C. albicans gene insertions/disruptions (pRC2312, pSF1-MPAr, pSF1-SAT1) will be used if the generation of additional recombinant strains becomes necessary. The plasmids are shuttle vectors for propagation in Escherichia coli and lactobacilli or C. albicans. Cell co-cultures will be evaluated with appropriate viability assays and gene/protein expression analyses. All work with C. albicans, any recombinant strains, and human cell lines will be conducted under BSL 2 containment.
NIH Guidelines Section	III-D-1, Appendix C-II, Appendix C-VI
Risk Assessment and Discussion	Risk Assessment: Generation of Splashes, Sprays or Aerosols from Centrifugation
	Discussion: Care should be taken to minimize the potential of splashes when handling liquids. Engineered controls, such as centrifuce comes and sealed rotors, should be used to ensure that aerosols are contained. Gloves, goggles, and lab coats should be worn at all times when handling agents listed on this application.
Training	All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.

Additional Training	No additional training concerns were noted by the IBC.	
Occupational Health Respresentative Review (if applicable)	No additional Occupational Health concerns were noted, researchers will follow standard occupational health enrollment procedures.	
Biosafety Level Assignment	Biosafety Level:	2
	Additional Discussion or notes:	All agents should be handled as if they were biohazardous; minimum PPE should be worn when working in the lab
IBC Vote	Motion:	Approve pending Changes 1st: BJ Reddig 2nd: Dr. Katz Amburn
	Votes, for/against/abstain/recused:	6/0/0/1
	Notes:	Dr. Koehler recused himself at 10:04am before discussion began, and returned at 10:25am after discussions had concluded. The remaining members requested a few minor revisions to the biosafety level listings of a few rooms, a change in one of the selections on the application, and requested a minor point of clarity with one section. The revisions to the application will be reviewed administratively by the Biosafety Officer.

New Business	Topic	Discussion
	Review and Update of IBC Bylaws - Non-Affiliated Members renewal, training, and/or re-training	With changes to the NIH-OSP coming due to modernization, the IBC did not make any changes to the bylaws. They determined to instead wait until more information comes out about the changes, and then they will modify the bylaws as needed. This is to allow for all necessary and desired changes to be made in one round or review so as to not overburden the Faculty Senate and the faculty members of the college with having to review the IBC bylaws multiple times within a year.

Additional/Other Business	NIH-OSP changes coming in the next year	Dr. Koehler brought up the notification from the NIH-OSP that changes are coming to their program in the next year. The IBC will watch these changes as they are released, and will prepare to make changes to the program as necessary.

Review of Incidents	No incidents were discussed at this meeting.
Inspections/Ongoing Oversight	No inspections or oversight are ongoing, and none were discussed at this meeting.
IBC Training	No continuing education occurred at this meeting.
Public Comments	No public comments were recorded at this meeting.
Adjournment	The IBC Chair moved to adjourn the meeting at 10:35am. The next IBC meeting is scheduled for Thursday, October 16 2025.